Allergen Profile With Total IgE, Respiratory−Area 12

TEST: 603719
Test number copied
CPT: 82785; 86003(x23)
Updated on 12/9/2024
Print Share

Test Includes

Area 12: Southern Arizona (desert area), Southern California (desert area)

Alternaria alternata; Aspergillus fumigatus; Bermuda grass; cat dander; cedar, mountain; Cladosporium herbarum; cockroach, German; cottonwood; Dermatophagoides farinae; Dermatophagoides pteronyssinus; dog dander; elm, American; Johnson grass; mimosa/acacia; mouse urine; mugwort; oak, white; olive tree; Penicillium chrysogenum; pigweed, rough; ragweed, short; rye grass, perennial; thistle, Russian

Expected Turnaround Time

3 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

3 - 4 days

3 - 5 days

Related Documents

For more information, please view the literature below.

Allergy Services: Identify and Manage Patients With Allergic Disease

Allergy Test Menu

    Specimen Requirements

    Specimen

    Serum

    Volume

    3.5 mL

    Container

    Red-top tube or gel-barrier tube

    Storage Instructions

    Room temperature

    Causes for Rejection

    Inadequate labeling; gross hemolysis

    Test Details

    Use

    Detect possible allergic responses to various substances in the environment (see Test Includes) and evaluate for hay fever, asthma, atopic eczema, and respiratory allergy. The quantitative allergen-specific IgE test is indicated (1) to determine whether an individual has elevated allergen-specific IgE antibodies; (2) if specific allergic sensitivity is needed to allow immunotherapy to be initiated; (3) when testing individuals for agents that may potentially cause anaphylaxis; (4) when evaluating individuals who are taking medication (eg, long-acting antihistamines) that may interfere with other testing modalities (eg, skin testing); (5) if immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; (6) when an individual is unresponsive to medical management where identification of offending allergens may be beneficial.

    Methodology

    Thermo Fisher ImmunoCAP®

    LOINC® Map

    For Providers

    Please login to order a test

    Order a Test

    © 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

    CPT Statement/Profile Statement

    The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf